<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812707</url>
  </required_header>
  <id_info>
    <org_study_id>DFI12361</org_study_id>
    <secondary_id>U1111-1134-4749</secondary_id>
    <nct_id>NCT01812707</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥100 mg/dL (≥2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein
      convertase subtilisin/kexin type 9 (PCSK9).

      Primary Objective of the study:

      To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels
      after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥100 mg/dL
      (≥2.59 mmol/L) on ongoing stable atorvastatin therapy.

      Secondary Objectives:

        -  To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment
           in comparison with placebo

        -  To evaluate the safety and tolerability of alirocumab

        -  To evaluate the development of anti-alirocumab antibodies

        -  To evaluate the pharmacokinetics of alirocumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study participation depended on the status of the participant at screening:
      21 to 27 weeks including a screening/run-in period of 1 to 7 weeks, a double-blind treatment
      period of 12 weeks, followed by an 8-week follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <description>Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward [LOCF] method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Calculated LDL-C &lt;100 mg/dL (2.59 mmol/L) and &lt; 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis</measure>
    <time_frame>Week 12 (LOCF)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <description>Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis</measure>
    <time_frame>From Baseline to Week 12 (LOCF)</time_frame>
    <description>Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alirocumab 50 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alirocumab 75 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alirocumab 150 mg Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab</intervention_name>
    <description>Two SC injections in the abdomen only</description>
    <arm_group_label>Alirocumab 50 mg Q2W</arm_group_label>
    <arm_group_label>Alirocumab 75 mg Q2W</arm_group_label>
    <arm_group_label>Alirocumab 150 mg Q2W</arm_group_label>
    <other_name>SAR236553</other_name>
    <other_name>RGEN727</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for alirocumab)</intervention_name>
    <description>Two subcutaneous (SC) injections in the abdomen only
Route of administration: subcutaneous injection (1 mL) in the abdomen</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Orally once daily at a stable dose of 5 to 20 mg as background therapy
Route of administration: oral administration in the evening</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alirocumab 50 mg Q2W</arm_group_label>
    <arm_group_label>Alirocumab 75 mg Q2W</arm_group_label>
    <arm_group_label>Alirocumab 150 mg Q2W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

        - Participants with primary hypercholesterolemia treated with atorvastatin at stable dose
        of 5-20 mg for at least 6 weeks prior to screening and likely to have LDL-C ≥100 mg/dL
        (≥2.59 mmol/L) at the screening visit.

        OR

        - Participants with primary hypercholesterolemia who were receiving a lipid-lowering
        treatment other than atorvastatin, or who were not at stable dose of atorvastatin 5-20 mg
        for at least 6 weeks prior to screening if they were likely to have LDL-C ≥100 mg/dL (≥2.59
        mmol/L) after a 6-week run-in treatment period on atorvastatin therapy.

        Exclusion criteria:

          1. LDL-C &lt;100 mg/dL (&lt;2.59 mmol/L)

               -  at screening visit for participants who were being treated with stable dose of
                  atorvastatin 5-20 mg for at least 6 weeks prior to screening OR

               -  at the end of the 6-week run-in period on atorvastatin for participants receiving
                  a lipid lowering treatment other than atorvastatin, or not at stable dose of
                  atorvastatin 5-20 mg for at least 6 weeks prior to screening

          2. Participants with type 1 diabetes

          3. Participants with type 2 diabetes treated with insulin, or without, and considered
             poorly controlled at screening.

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Koganei-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, Inoue S, Minami F, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016 Jul 1;118(1):56-63. doi: 10.1016/j.amjcard.2016.04.011. Epub 2016 Apr 21.</citation>
    <PMID>27184170</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <results_first_submitted>August 21, 2015</results_first_submitted>
  <results_first_submitted_qc>August 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2015</results_first_posted>
  <disposition_first_submitted>January 22, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 30, 2015</disposition_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 4 centers in Japan. Overall, 162 participants were screened between March 2013 and August 2013, 62 of whom were run-in/screen failures, mainly due to exclusion criteria met.</recruitment_details>
      <pre_assignment_details>Randomization was stratified according to atorvastatin dose. Assignment to treatment arms was done centrally using an Interactive Voice/Web Response System in a 1:1:1:1 ratio after confirmation of selection criteria. 100 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="P2">
          <title>Alirocumab 50 mg Q2W</title>
          <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="P3">
          <title>Alirocumab 75 mg Q2W</title>
          <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="P4">
          <title>Alirocumab 150 mg Q2W</title>
          <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn by participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized population.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="B2">
          <title>Alirocumab 50 mg Q2W</title>
          <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="B3">
          <title>Alirocumab 75 mg Q2W</title>
          <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="B4">
          <title>Alirocumab 150 mg Q2W</title>
          <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="9.2"/>
                    <measurement group_id="B2" value="57.8" spread="12.3"/>
                    <measurement group_id="B3" value="56.3" spread="12.0"/>
                    <measurement group_id="B4" value="58.2" spread="8.8"/>
                    <measurement group_id="B5" value="57.7" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.13" spread="0.55"/>
                    <measurement group_id="B2" value="3.16" spread="0.43"/>
                    <measurement group_id="B3" value="3.13" spread="0.43"/>
                    <measurement group_id="B4" value="3.12" spread="0.42"/>
                    <measurement group_id="B5" value="3.14" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C in mg/dL</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.0" spread="21.1"/>
                    <measurement group_id="B2" value="122.2" spread="16.6"/>
                    <measurement group_id="B3" value="120.9" spread="16.7"/>
                    <measurement group_id="B4" value="120.5" spread="16.2"/>
                    <measurement group_id="B5" value="121.2" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis</title>
        <description>Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward [LOCF] method.</description>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>Modified Intent-To-Treat (mITT) population included all randomized participants with one baseline and at least one post-baseline calculated LDL-C value on-treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis</title>
          <description>Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward [LOCF] method.</description>
          <population>Modified Intent-To-Treat (mITT) population included all randomized participants with one baseline and at least one post-baseline calculated LDL-C value on-treatment.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="3.1"/>
                    <measurement group_id="O2" value="-54.8" spread="3.1"/>
                    <measurement group_id="O3" value="-62.3" spread="3.1"/>
                    <measurement group_id="O4" value="-71.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Each treatment group was compared to placebo using ANCOVA-derived contrasts.
A hierarchical testing procedure was applied to ensure strong control of overall Type-I error rate at 0.05 level. Order was following:
Alirocumab 150 mg Q2W versus placebo
Alirocumab 75 mg Q2W versus placebo
Alirocumab 50 mg Q2W versus placebo
Testing continued only when high-order test was statistically significant at 5% level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance ≤0.05</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance ≤0.05</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for significance ≤0.05</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis</title>
        <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis</title>
          <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
          <population>mITT population.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.1"/>
                    <measurement group_id="O2" value="-1.7" spread="0.1"/>
                    <measurement group_id="O3" value="-1.9" spread="0.1"/>
                    <measurement group_id="O4" value="-2.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis</title>
        <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis</title>
          <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
          <population>mITT population.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="3.6"/>
                    <measurement group_id="O2" value="-67.1" spread="3.6"/>
                    <measurement group_id="O3" value="-74.6" spread="3.6"/>
                    <measurement group_id="O4" value="-85.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Calculated LDL-C &lt;100 mg/dL (2.59 mmol/L) and &lt; 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis</title>
        <time_frame>Week 12 (LOCF)</time_frame>
        <population>mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Calculated LDL-C &lt;100 mg/dL (2.59 mmol/L) and &lt; 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis</title>
          <population>mITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C &lt;100 mg/dL (2.59 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C &lt; 70 mg/dL (1.81 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="84.0"/>
                    <measurement group_id="O4" value="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis</title>
        <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>Participants of the mITT population with one baseline and at least one post baseline on-treatment value of lipid parameters analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis</title>
          <description>Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.</description>
          <population>Participants of the mITT population with one baseline and at least one post baseline on-treatment value of lipid parameters analyzed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.1"/>
                    <measurement group_id="O2" value="-31.9" spread="2.1"/>
                    <measurement group_id="O3" value="-36.3" spread="2.1"/>
                    <measurement group_id="O4" value="-41.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.0"/>
                    <measurement group_id="O2" value="5.1" spread="2.0"/>
                    <measurement group_id="O3" value="5.0" spread="2.0"/>
                    <measurement group_id="O4" value="3.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.9"/>
                    <measurement group_id="O2" value="-46.3" spread="2.9"/>
                    <measurement group_id="O3" value="-53.1" spread="2.9"/>
                    <measurement group_id="O4" value="-62.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apo-B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="3.3"/>
                    <measurement group_id="O2" value="-43.5" spread="3.3"/>
                    <measurement group_id="O3" value="-48.6" spread="3.3"/>
                    <measurement group_id="O4" value="-60.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis</title>
        <description>Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).</description>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>Participants of the mITT population with one baseline and at least one post baseline on-treatment value of Fasting Triglycerides and Lipoprotein (a) analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis</title>
          <description>Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).</description>
          <population>Participants of the mITT population with one baseline and at least one post baseline on-treatment value of Fasting Triglycerides and Lipoprotein (a) analyzed.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-13.1" upper_limit="22.5"/>
                    <measurement group_id="O2" value="-21.1" lower_limit="-28.2" upper_limit="4.2"/>
                    <measurement group_id="O3" value="-10.7" lower_limit="-25.0" upper_limit="6.5"/>
                    <measurement group_id="O4" value="-15.0" lower_limit="-24.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipoprotein (a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-26.2" upper_limit="8.4"/>
                    <measurement group_id="O2" value="-35.6" lower_limit="-52.5" upper_limit="-7.5"/>
                    <measurement group_id="O3" value="-40.2" lower_limit="-62.9" upper_limit="-27.4"/>
                    <measurement group_id="O4" value="-43.3" lower_limit="-69.4" upper_limit="-14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis</title>
        <description>Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.</description>
        <time_frame>From Baseline to Week 12 (LOCF)</time_frame>
        <population>Participants of the mITT population with one baseline and at least one post baseline on-treatment value of ApoB/ApoA-1 ratio analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for alirocumab) Q2W for 12 weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O2">
            <title>Alirocumab 50 mg Q2W</title>
            <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O3">
            <title>Alirocumab 75 mg Q2W</title>
            <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
          <group group_id="O4">
            <title>Alirocumab 150 mg Q2W</title>
            <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis</title>
          <description>Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.</description>
          <population>Participants of the mITT population with one baseline and at least one post baseline on-treatment value of ApoB/ApoA-1 ratio analyzed.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                    <measurement group_id="O2" value="-0.30" spread="0.02"/>
                    <measurement group_id="O3" value="-0.32" spread="0.02"/>
                    <measurement group_id="O4" value="-0.38" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational medicinal product (IMP).</time_frame>
      <desc>Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the ‘treatment emergent period’ (the time from the first dose to the last dose of IMP + 70 days). Safety population: participants who received at least one dose or partial dose of IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo Q2W for 12 weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="E2">
          <title>Alirocumab 50 mg Q2W</title>
          <description>Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="E3">
          <title>Alirocumab 75 mg Q2W</title>
          <description>Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
        <group group_id="E4">
          <title>Alirocumab 150 mg Q2W</title>
          <description>Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact ­-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

